mRNA Therapy for Cardiovascular Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 31 August 2026 | Viewed by 286
Special Issue Editor
Interests: gene expression regulation; noncoding RNAs; pharmaceuticals; molecular markers
Special Issue Information
Dear Colleagues,
Cardiovascular diseases (CVDs) represent the leading cause of mortality worldwide and are responsible for approximately one-third of all global deaths annually. Given that the pathogenesis of CVDs, including coronary artery disease, hypertension, stroke, and heart failure, is a complex and multifactorial process, their effective management requires innovative therapeutic strategies that exceed the current standard of care and improve patient outcomes by potentially altering the course of CVDs. mRNA therapeutics, which can directly modulate cellular functions by delivering specific mRNA molecules to target cells without their insertion into the genome, have recently emerged as a promising strategy in the context of CVD management. The ability to adjust mRNA therapy to an individual's clinical and genetic profiles represents an advancement of personalized medicine, potentially offering increased treatment efficacy and specificity.
This Special Issue aims to provide a comprehensive overview of current advances in the development of mRNA therapeutics for the treatment of CVDs while encouraging discussion of future strategies to improve their efficacy. We invite articles on all aspects of developing cell-specific mRNA therapeutics that may intervene at different stages of CVD pathogenesis by modulating the expression of regulatory genes involved in inflammation, cardiomyocyte proliferation, angiogenesis, and tissue repair. In addition, we are interested in papers reporting methods that improve the targeted delivery of mRNA to cardiomyocytes and other relevant cell types, as well as studies analyzing the off-target effects, immunogenicity, and stability of mRNA therapies for CVDs.
Original research papers and review articles are welcome.
Dr. Mirjana Macvanin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiovascular diseases
- mRNA therapeutics
- modRNA
- gene therapy
- cardiomyocyte
- heart failure
- myocardial infarction
- delivery systems
- regenerative therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
